<DOC>
	<DOCNO>NCT00820963</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Giving radiation therapy high dos shorter period time may kill tumor cell few side effect . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether standard radiation therapy , higher-dose radiation therapy , chemotherapy effective treat old patient glioblastoma multiforme . PURPOSE : This randomized phase III trial study standard radiation therapy see well work compare higher-dose radiation therapy chemotherapy treat old patient glioblastoma multiforme .</brief_summary>
	<brief_title>Standard Radiation Therapy , Higher-Dose Radiation Therapy , Chemotherapy Treating Older Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient 60 glioblastoma multiforme treat standard radiotherapy v hypofractionated radiotherapy v chemotherapy . Secondary - Compare quality life ( QLQ-C30 ) patient . - Compare safety , tolerance , toxicity regimen . - Assess pharmacoeconomic cost regimen . OUTLINE : This multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients undergo standard radiotherapy 5 day week 6 week . - Arm II : Patients undergo hypofractionated radiotherapy 5 day week 2 week . - Arm III : Patients receive oral temozolomide day 1-5 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme Grade 4 disease ( WHO ) PATIENT CHARACTERISTICS : WHO performance status ( PS ) 02 ( PS 34 allow secondary neurological physical handicap ) Life expectancy ≥ 3 month ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Transaminases ≤ 3 time ULN Creatinine &lt; 1.5 time ULN Able tolerate 3 treatment option No malignancy within past 5 year except curatively treat basal cell squamous cell carcinoma skin No acute chronic severe illness , investigator 's opinion , contraindicate participation study PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , immunotherapy Concurrent corticosteroid allow provided patient receive low dose necessary optimal functioning</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>